Aeglea BioTherapeutics, Inc. Profile Avatar - Palmy Investing

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recomb…

Biotechnology
US, Austin [HQ]
Competitors · Subsidiaries · Locations

Business Intelligence

U.S. · Business Intelligence
Worldwide · Business Intelligence
Worldwide · Subsidiaries Table
Subsidiary Private? Country City
- - - -
End of AGLE's Analysis
CIK: 1636282 CUSIP: 00773J103 ISIN: US00773J2024 LEI: - UEI: -
Secondary Listings
AGLE has no secondary listings inside our databases.